Teva Gets High Court Extension to Challenge Orange Book Ruling

Chief Justice John Roberts gave Teva Pharmaceutical Industries Ltd. until July 31 to file a petition challenging an appeals court ruling it argued puts hundreds of patents at risk under a new interpretation of federal drug laws.

Roberts in a Thursday order granted Teva’s May 22 request for more time, which it said was necessary for its petition challenging the US Court of Appeals for the Federal Circuit’s Dec. 20 decision. Teva plans to argue the appeals court misinterpreted federal drug law—specifically, Hatch-Waxman, the law that governs the approval of brand-name and generic drugs—and conflicts with prior Supreme ...